Methyl donor to homocysteine via betaine-homocysteine methyltransferase (BHMT) — a B12-independent remethylation route parallel to methionine synthase. Complementary methyl donor for high-methylation-demand protocols (e.g., NMN → NAD⁺ → methylated nicotinamide). Also a renal osmolyte and a performance-enhancement ergogenic at ~2.5 g/d (mechanism uncertain — possibly via methyl support for creatine synthesis).
Half-Life & Elimination Curve (PO: 2h)
Plasma (PO)t½ Decay (2h)
0×t½0h100%(9.77 mg/L)
1×t½2h50%(4.89 mg/L)
2×t½4h25%(2.44 mg/L)
3×t½6h12.5%(1.22 mg/L)
4×t½8h6.3%(0.611 mg/L)
5×t½10h3.1%(0.305 mg/L)
Elimination t½2h (PO)
Rate Constant (ke)0.347 h⁻¹
Time to Peak (Tmax)1.27h
Est. Peak (Cmax)9.77 mg/L
Clearance (CL)9.7 L/h
97% Washout (5×t½)10h
Dosing Guidelines
Oral (PO): Typical 500 mg
Pharmacokinetic Parameters
Oral (PO): Bioavailability (F): 85% · Volume of Distribution (Vd): 28 L · Absorption (ka): 1.5 h⁻¹ (t½ka ≈ 28m) [PMID 16365055]